NL-OMON36291
Completed
Not Applicable
An Evaluation of the Safety and Pharmacokinetics of Posaconazole (POS, SCH 56592) IV Solution via Peripheral Administration in Healthy Volunteers (P06356) - P06356
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Fungal infections
- Sponsor
- Merck
- Enrollment
- 96
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy male and female
Exclusion Criteria
- •Clinical significant abnormalities at medical research
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
P06356EUCTR2010-020832-20-NLSchering-Plough Research Institute, a Division of Schering Corporation - for Global trials96
Not yet recruiting
Phase 1
Safety and pharmacokinetics of CIGB-552Solid tumorsRPCEC00000196Center for Genetic Engineering and Biotechnology (CIGB)
Completed
Not Applicable
A Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Doses of LY3526318 in Healthy ParticipantsNL-OMON50998Eli Lilly16
Active, not recruiting
Phase 1
Safety, Tolerability and Pharmacokinetics of Tirzepatide in Pediatric Participants with Obesity.Weight managementMedDRA version: 20.0Level: HLTClassification code 10027428Term: Metabolic disorders NECSystem Organ Class: 100000004861Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]EUCTR2024-000081-22-Outside-EU/EEAEli Lilly and Company
Recruiting
Phase 1
Phase 1 study of 211At-MABG in patients with pheochromocytoma/pargangliomaPheochromocytoma, paragangliomaD010673, D010235JPRN-jRCT2021220012Shiga Tohru18